Dermapharm Holding SE - Asset Resilience Ratio
Dermapharm Holding SE (DMP) has an Asset Resilience Ratio of 1.23% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See DMP working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Dermapharm Holding SE's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Dermapharm Holding SE assets under control.
Liquid Assets Composition Over Time
This chart breaks down Dermapharm Holding SE's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Dermapharm Holding SE (DMP) investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €28.06 Million | 1.23% |
| Total Liquid Assets | €28.06 Million | 1.23% |
Asset Resilience Insights
- Limited Liquidity: Dermapharm Holding SE maintains only 1.23% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Dermapharm Holding SE Industry Peers by Asset Resilience Ratio
Compare Dermapharm Holding SE's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Neuland Laboratories Limited
NSE:NEULANDLAB |
Drug Manufacturers - Specialty & Generic | 9.65% |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062 |
Drug Manufacturers - Specialty & Generic | 1.18% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
Annual Asset Resilience Ratio for Dermapharm Holding SE (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Dermapharm Holding SE.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.03% | €735.00K ≈ $859.29K |
€2.20 Billion ≈ $2.58 Billion |
+0.01pp |
| 2024-12-31 | 0.02% | €511.00K ≈ $597.41K |
€2.08 Billion ≈ $2.43 Billion |
-7.36pp |
| 2023-12-31 | 7.38% | €159.50 Million ≈ $186.47 Million |
€2.16 Billion ≈ $2.53 Billion |
-4.11pp |
| 2022-12-31 | 11.50% | €162.43 Million ≈ $189.89 Million |
€1.41 Billion ≈ $1.65 Billion |
-0.81pp |
| 2021-12-31 | 12.30% | €173.12 Million ≈ $202.40 Million |
€1.41 Billion ≈ $1.64 Billion |
+2.40pp |
| 2020-12-31 | 9.91% | €121.30 Million ≈ $141.81 Million |
€1.22 Billion ≈ $1.43 Billion |
-1.17pp |
| 2019-12-31 | 11.08% | €115.77 Million ≈ $135.34 Million |
€1.04 Billion ≈ $1.22 Billion |
-19.23pp |
| 2018-12-31 | 30.31% | €213.57 Million ≈ $249.69 Million |
€704.58 Million ≈ $823.73 Million |
+28.71pp |
| 2017-12-31 | 1.60% | €6.64 Million ≈ $7.76 Million |
€415.30 Million ≈ $485.53 Million |
+0.36pp |
| 2016-12-31 | 1.23% | €3.85 Million ≈ $4.50 Million |
€311.70 Million ≈ $364.41 Million |
+1.22pp |
| 2015-12-31 | 0.01% | €29.00K ≈ $33.90K |
€296.67 Million ≈ $346.83 Million |
-0.03pp |
| 2014-12-31 | 0.04% | €120.00K ≈ $140.29K |
€330.60 Million ≈ $386.50 Million |
+0.00pp |
| 2013-12-31 | 0.03% | €120.00K ≈ $140.29K |
€349.98 Million ≈ $409.16 Million |
-- |
About Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. The company operates through three segments: Branded Pharmaceuticals; Other Healthcare Products; and Parallel Import Business. It offers br… Read more